An Adaptive, Randomized, Active-controlled, Open-label, Sequential Cohort, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Intravenous Cipargamin (KAE609) in Adult and Pediatric Participants With Severe Plasmodium Falciparum Malaria (KARISMA - KAE609's Role In Severe Malaria)
Latest Information Update: 02 Apr 2025
At a glance
- Drugs Cipargamin (Primary) ; Artemether/lumefantrine; Artesunate
- Indications Falciparum malaria; Malaria
- Focus Therapeutic Use
- Acronyms KARISMA
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 28 Mar 2025 Planned End Date changed from 27 Sep 2025 to 26 Sep 2025.
- 31 Dec 2024 Planned End Date changed from 20 May 2025 to 27 Sep 2025.
- 31 Dec 2024 Planned primary completion date changed from 20 May 2025 to 30 Aug 2025.